

和中国公司合作的最佳策略

**China's Attraction
and
Strategies to Work with It**

**–Analysis of Best Strategies for Western
Pharmaceutical and Biotech Companies to Partner with
Chinese Pharmaceutical Companies**

By Jim J. Zhang, Ph.D.

July, 2008



Table of Contents

Executive Summary

Chapter 1. Introduction: Difficulties experienced currently by Western pharmaceutical industry and attractions China presents

- 1.1 Western pharmaceutical industry is currently experiencing downturn
- 1.2 Factors negatively affecting the Western pharmaceutical industry
- 1.3 Passive actions currently taken by Western pharmaceutical industry
- 1.4 Attractions China presents
 - 1.4.1 China is presenting an attractive pharmaceutical market to Western pharma/biotech companies
 - 1.4.2 China can offer to Western companies a vast pool of talented, skilled workforce
 - 1. The vast pool of skilled workforce in China is an alternative resource to Western companies to increase productivity
 - 2. The alternative labor resource is also low cost
- 1.5 Do not miss the “Bus” – Potential consequences if not promptly targeting the Chinese pharmaceutical market or timely taking the best use of what is readily available in China
- 1.6 Summary
 - 1. Entire world pharmaceutical industry is experiencing difficult time
 - 2. Targeting the growing Chinese pharmaceutical market or partnering with Chinese companies has become a must
 - 3. Current development trend in partnering with Chinese companies
 - 4. Challenges encountered by Western companies when entering Chinese market

Chapter 2. What do Western pharmaceutical and biotech industry urgently need at this moment?

- 2.1 Cost reduction is one of the main goals – Case studies to illustrate the strategies currently pursued by major pharma/biotech companies and analysis of their essential motivations
 - 2.1.1 Case illustration
 - 2.1.2 Analysis of motivations
- 2.2 Cost reduction is not the only goal – An in-depth analysis of advantages and disadvantages of the actions currently undertaken by Western pharma/biotech companies
 - 2.2.1 All possible options available to Western pharma/biotech companies
 - 2.2.2 Analysis of advantages and disadvantages of each option

1. Partnering with small-sized biotech companies or licensing drug candidates from them
 - Advantages
 - Disadvantages
 - Why is that? In-depth analysis of disadvantages
 - i. Rationale 1
 - ii. Rationale 2
 - iii. Rationale 3
2. Restructuring own organization in order to improve efficiency
 - Advantages
 - Disadvantages
3. Increasing outsourcing to more extensively utilize the external resources
 - Advantages
 - Disadvantages
4. Focusing on emerging pharmaceutical markets
 - Advantages
 - Disadvantages

2.3 Summary

Chapter 3. What can China offer to help at this moment? – A review of entire Chinese pharmaceutical industry

- 3.1 Introduction
- 3.2 Structure of Chinese pharmaceutical industry has changed dramatically over past two decades
- 3.3 What can Chinese pharmaceutical companies offer to help Western companies? – A review of current research and service capabilities of entire Chinese pharmaceutical industry
 - 3.3.1 Chinese pharmaceutical companies: major players and their current capabilities
 - 3.3.2 Fast growing Chinese biotech industry
 - 3.3.3 China's contract pharmaceutical research industry (CROs)
 - 3.3.4 China's contract pharmaceutical manufacturing industry (CMOs)

Chapter 4. How to best use the resources readily available in China – Analysis of Strategies

- 4.1 Introduction
- 4.2 Identifying the areas in drug R&D and manufacturing that require to be addressed urgently
- 4.3 Most costly sectors in entire process of drug R&D and manufacturing
 - 4.3.1 Brief description of drug discovery, development and manufacturing process
 - 4.3.2 Analysis of cost structure of entire process
 - 4.3.3 Identification of the most costly sectors

- 4.3.4 Most frequently failed sectors in drug R&D
- 4.3.5 Analysis of the factors contributing to failures of a drug trial
- 4.4 Chinese companies' capabilities in these most costly and frequently failed areas
 - 4.4.1 Custom synthesis of large scale compound libraries that possess structural feature of drug molecules (or so-called drug-like molecules)
 - 4.4.2 Pharmacological property studies
 - 4.4.3 *In vivo* preclinical research
 - 4.4.4 Clinical research
 - 4.4.5 Contract manufacturing
- 4.5 Matching China's current capabilities with the urgent needs of Western pharma/biotech companies
- 4.6 Strategies to work with China and Chinese companies
 - 4.6.1 Marketing pharmaceutical products in China
 - 4.6.2 Tapping the abundant and low-cost labor resources in China
 - 4.6.3 How to tap the low-cost labor
 - i. Establishing a wholly owned facility
 - ii. Forming a joint venture (JV)
 - iii. Forming a partnership
 - iv. Outsourcing (or contracting out)
 - v. Sourcing the low-cost materials in China
- 4.7 Advantages and disadvantages of each strategy for entering Chinese market
 - 4.7.1 Marketing pharmaceutical products in China
 - i. Who can go to China
 - ii. Challenges
 - iii. How to overcome these hurdles
 - 4.7.2 Tapping low-cost labor in China
 - 1. Establishing a wholly owned facility
 - i. Advantages
 - ii. Disadvantages
 - 2. Forming a joint venture (JV)
 - i. Advantages
 - ii. Disadvantages
 - iii. Strategies to safeguard IP and products
 - 3. Partnership
 - i. Advantages
 - ii. Disadvantages
 - 4. Outsourcing
 - i. Advantages
 - ii. Keys to gain these advantages
 - iii. Disadvantages
- 4.8 Evaluating the best strategies to tap Chinese market
 - 4.8.1 Case studies
 - 4.8.2 Best strategies to outsource to China at present time: to all sized companies
 - 4.8.3 Best strategies to tap resources in China: specifically to small and medium-sized pharma/biotech companies

- 4.9 Who are in China at present time and what are they doing there?
 - 4.9.1 Case studies
 - 1. Novartis setting up wholly owned R&D center in Shanghai to focus on diseases popular in China
 - 2. AstraZeneca implementing a full scope of collaborations with China
 - 3. Pfizer conducting a broad scope of drug manufacturing and selling in China
 - 4.9.2 Summaries of major Western companies and their activities in China (including 22 major pharma/biotech companies, 10 small biotech companies, 10 multinational CROs, 10 generic drug makers, and 10 investment companies)
- 4.10 Building own facility in China or contracting out there?
- 4.11 Must the outsourcing strategy be incorporated into long term business development goal? – An analysis of differences between partnership and pure outsourcing
 - 4.11.1 Partnership
 - i. Activities involved in a partnership
 - ii. Purposes of a partnership
 - iii. Characteristics of a partnership
 - 4.11.2 Outsourcing
 - i. Activities involved in outsourcing
 - ii. Purposes of outsourcing
 - iii. Characteristics of outsourcing
 - 4.11.3 Summary

Chapter 5. How to effectively collaborate with Chinese companies?

- 5.1 Introduction
- 5.2 Differences in business conduct between the West and the East
 - 5.2.1 Long-term business development goals versus short term business development goals
 - 5.2.2 Assumed responsibility versus required responsibility
 - 5.2.3 Consistency versus randomness
 - 5.2.4 Business relationship versus personal relationship
 - 5.2.5 Summary of the characteristics of Chinese culture in business conduct
- 5.3 Strategies for effectively collaborating with Chinese companies
 - 5.3.1 Select a Chinese partner/vendor carefully
 - 5.3.2 Pay attention to relationship
- 5.4 Strategies to avoid conflicts and loss of IPs
- 5.5 Strategies to resolve issues/disputes in conducting business collaboration with a Chinese company
 - 5.5.1 Quality issue
 - 5.5.2 IP breach

Appendixes

Appendix I. Author's Biography
Appendix II. About JZMed, Inc.

List of Tables

- Table 1. Growth rates of world major pharmaceutical markets (year 2007)
- Table 2. Growth rates of major pharma/biotech companies' revenue/profit
- Table 3. Comparison of labor costs (FTE rates) in various places of the world
- Table 4. Survey results of pharma/biotech companies interested in outsourcing to China (or India)
- Table 5. Major Chinese pharmaceutical companies and their capabilities
- Table 6. Major Chinese biotech companies and their capabilities
- Table 7. Best China-based CROs and their service capabilities
- Table 8. Best China-based CMOs and their service capabilities
- Table 9. Cost analysis of drug discovery, development and manufacturing process
- Table 10. Matching between the needs by Western pharma/biotech companies and capabilities and readily available resources in China
- Table 11. Major Western pharma/biotech companies in China
- Table 12. Small-sized Western pharma/biotech companies in China
- Table 13. Multinational CROs in China
- Table 14. Western generic drug manufacturers in China
- Table 15. Foreign investors in China
- Table 16. Comparison between partnership and pure outsourcing
- Table 17. Major characteristics of Chinese culture in business conduct

List of Figures

- Figure 1. Distributions of the number of China-based CROs/CMOs in each technical area of entire drug discovery, development and manufacturing process
- Figure 2. Description of entire drug discovery, development and manufacturing process